BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its ...

BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values ...

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an ...

BioNTech has announced that it will be expanding its messenger RNA (mRNA) capabilities by acquiring CureVac for approximately ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two ...